Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

Merck Begins Enrolling Patients In A Late-Stage Trial Of Its COVID-19 Experimental Drug Molnupiravir

By John F. Heerdink, Jr.

Reportedly, Merck & Co., Inc. (MRK) and partner Ridgeback Biotherapeutics have begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for the prevention of COVID-19 infection. The drug will be administered and studied in over 1,300 volunteers to determine if it can prevent the spread of the coronavirus. The study is enrolling participants who are at least 18 years of age and stay in the same household with someone infected with the symptomatic COVID-19 virus.

In June, Merck informed that the U.S. government has agreed to pay about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment if it is proven to work in a separate, ongoing large trial and authorized by U.S. regulators.

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
(Read Original Story: UPDATE 1-Merck begins late-stage trial of experimental COVID-19 drug in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us